Education
About Us
Working with TipRanks
Follow Us
Defence Therapeutics (TSE:DTC)
:DTC
DTC Stock Chart & Stats
Day’s Range― - ―
52-Week RangeC$0.48 - C$1.92
Previous CloseN/A
Volume0.00
Average Volume (3M)134.20K
Market Cap
$61.29M
Enterprise ValueC$26.76M
Total Cash (Recent Filing)C$130.52K
Total Debt (Recent Filing)C$1.28M
Price to Earnings (P/E)―
Beta0.07
Next Earnings
May 23, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.09
Shares Outstanding54,725,370
10 Day Avg. Volume82,281
30 Day Avg. Volume134,198
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-22.10
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
---
Defence Therapeutics News
PremiumCompany Announcements
Defence Therapeutics Secures $3.9 Million to Boost Biotech Initiatives
PremiumCompany Announcements
Defence Therapeutics Strengthens Patent Portfolio, Secures Market Exclusivity
PremiumCompany Announcements
Defence Therapeutics Announces $4.2M Private PlacementPremiumCompany Announcements
Defence Therapeutics Strengthens Leadership with Key Appointments
PremiumCompany Announcements
IC Capitalight Reports New Exploration ResultsPremiumCompany Announcements
Defence Therapeutics to License Accum TechnologyPremiumCompany Announcements
Defence Therapeutics Welcomes New CSO to Drive Growth---
Options Prices
Currently, No data available
---
Ownership Overview
DTC FAQ
What was Defence Therapeutics’s price range in the past 12 months?
Defence Therapeutics lowest stock price was C$0.48 and its highest was C$1.92 in the past 12 months.
What is Defence Therapeutics’s market cap?
Defence Therapeutics’s market cap is $61.29M.
When is Defence Therapeutics’s upcoming earnings report date?
Defence Therapeutics’s upcoming earnings report date is May 23, 2025 which is in 72 days.
How were Defence Therapeutics’s earnings last quarter?
Defence Therapeutics released its earnings results on Feb 25, 2025. The company reported -C$0.017 earnings per share for the quarter, missing the consensus estimate of N/A by -C$0.017.
Is Defence Therapeutics overvalued?
According to Wall Street analysts Defence Therapeutics’s price is currently Overvalued.
Does Defence Therapeutics pay dividends?
Defence Therapeutics does not currently pay dividends.
What is Defence Therapeutics’s EPS estimate?
Defence Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Defence Therapeutics have?
Defence Therapeutics has 54,725,370 shares outstanding.
What happened to Defence Therapeutics’s price movement after its last earnings report?
Defence Therapeutics reported an EPS of -C$0.017 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 27.273%.
Which hedge fund is a major shareholder of Defence Therapeutics?
Currently, no hedge funds are holding shares in TSE:DTC
---
Company Description
Defence Therapeutics
Defence Therapeutics Inc is engaged in the development of anti-body drug conjugates that improve the efficacy and safety of nano and protein-based pharmaceuticals used in the treatment of cancer.
---
Technical Analysis
---